Low soluble thrombomodulin activity and antigen is associated with a family history of heart disease while a high level is associated with a personal history of heart disease in type 2 diabetes [4]

Thrombosis and Haemostasis

Volumn 97, Issue 1, 2007, Pages 161-164

  Konstantoulas, Constantine J ^a   Cooper, Jackie A ^a   Ohlin, Ann Kristin ^b   Humphries, Stephen E ^a   Goodall, Alison H ^c   Toh, Cheng Hoc ^d   Mather, Hugh ^e   Ireland, Helen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e EALING HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; THROMBOMODULIN; UREA;

ANGIOGRAPHY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; ELECTROCARDIOGRAM; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART DISEASE; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SYMPTOM; THORAX PAIN; THROMBOGENICITY; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

DIABETES MELLITUS, TYPE 2; FAMILY HEALTH; HEART DISEASES; HUMANS; RISK FACTORS; SOLUBILITY; THROMBOMODULIN;

EID: 33847007330     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-03-0160     Document Type: Letter

References (22)

1. Esmon CT. Regulation of blood coagulation. Biochim Biophys Acta 2000; 1477: 349-60.
2. Ishii H, Majerus PW. Thrombomodulin is present in human plasma and urine. J Clin Invest 1985; 76: 2178-81.
3. Uehara S, Gotoh K, Handa H. Separation and characterization of the molecular species of thrombomodulin in the plasma of diabetic patients. Thromb Res 2001; 104: 325-32.
4. Inukai T, Fujiwara Y, Tayama K, et al. Clinical significance of measurements of urinary and serum thrombomodulins in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1996; 33: 99-104.
5. Ohlin AK, Morser J, Ohlin H. Soluble thrombomodulin antigen in plasma is increased in patients with acute myocardial infarction treated with thrombolytic therapy. Thromb Res 1996; 92: 313-22.
6. Takano S, Kimura S, Ohdama S, et al. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-9.
7. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost 1991; 65: 618-23.
8. Blann AD, Seigneur M, Steiner M, et al. Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 1997; 27: 916-21.
9. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001; 15: 44-54.
10. Li YH, Chen JH, Wu HL, et al. G-33A mutation in the promoter region of thrombomodulin gene and its association with coronary artery disease and plasma soluble thrombomodulin levels. Am J Cardiol 2000; 85: 8-12.
11. Kunz G, Ireland HA, Stubbs PJ, et al. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. Blood 2000; 95: 569-76.
12. Salomaa V, Matei C, Aleksic N, et al. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 1729-34.
13. Ireland H. Konstantoulas CJ, Cooper JA, et al. EPCR Ser2l9Gly: elevated sEPCR, prothrombin F1+2, risk for coronary heart disease, and increased sEPCR shedding in vitro. Atherosclerosis 2005; 183: 283-92.
14. Ohlin AK, Larsson K, Hansson M. Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma. J Thromb Haemost 2005; 3: 976-82.
15. Bland JM, Altman DG. Multiple significance tests: the Bonferrom method. Br Med J 1995; 310: 170.
16. Oida K, Takai H, Maeda H, et al. Plasma thrombomodulin concentration in diabetes mellitus. Diabetes Res Clin Pract 1990; 10: 193-6.
17. Hergesell O, Andrassy K, Geberth S, et al. Plasma thrombomodulin levels are dependent on renal function. Thromb Res 1993; 72: 455-8.
18. Weiner DE, Tighiouart H, Stark PC, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44: 198-206.
19. Mann JF, Gerstein HC, Pogue J, et al. Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. Am J Cardiovasc Drugs 2002; 2: 157-62.
20. Luria MH, Knoke JD, Margolis RM, et al. Acute myocardial infarction: prognosis after recovery. Ann Intern Med 1976; 85: 561-5.
21. Normand ST, Glickman ME, Sharma RG, et al. Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients. Results from the Cooperative Cardiovascular Project. J Am Med Assoc 1996; 275: 1322-8.
22. Kirtane AJ, Leder DM, Waikar SS, et al. Serum blood urea nitrogen as an independent marker of subsequent mortality among patients with acute coronary syndromes and normal to mildly reduced glomerular filtration rates. J Am Coll Cardiol 2005; 45: 1781-6.